Company InfoNewsInvestor InformationResearchDevelopmentCareersBusiness DevelopmentResourcesDrugs databaseBack to the home pageSearch  
Drugs database
Drugs A-Z

Brands A-Z

Drugs by categories

Drugs by manufacturer

Drugs by packager

Antibiotics for sale

Online Viagra bestellen in Nederland

Home / Drugs / Starting with P / Plerixafor

Plerixafor is a hematopoietic stem cell mobilizer. It is used to stimulate the release of stem cells from the bone marrow into the blood in patients with non-Hodgkin lymphoma and multiple myeloma. These stem cells are then collected and used in autologous stem cell transplantation to replace blood-forming cells that were destroyed by chemotherapy. Plerixafor has orphan drug status in the United States and European Union; it was approved by the U.S. Food and Drug Administration on December 15, 2008.


Used in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM).


Plerixafor increases circulating CD34+ cells in the peripheral blood, with a peak effect about 6-9 hours.

mechanism of action

Plerixafor inhibits the CXCR4 chemokine receptor and blocks binding to the marrow compartment of its cognate ligand, SDF-1alpha, which play a role in the trafficking and homing of human hematopoietic stem cells.


Plerixafor is rapidly absorbed after subcutaneous injection (Tmax = 30-60 min).

half life

Terminal half-life ranges from 3 to 5 hours.

route of elimination

Approximately 70% of the parent drug is excreted in urine during first 24 h.